Evidence map›Paper›PMID 42124621›Full record

ArticlebioRxiv : the preprint server for biology2026

Proteomic Screening Identifies HNRNPA2B1 as an Epigenetic Repressor of Epstein-Barr Virus Reactivation.

Febri Gunawan Sugiokto, Yuxin Liu, Renfeng Li

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Febri Gunawan SugioktoProgram in Microbiology and Immunology, University of Pittsburgh, Pittsburgh, PA 15219, USA.
Yuxin LiuDepartment of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA 15219, USA.
Renfeng LiProgram in Microbiology and Immunology, University of Pittsburgh, Pittsburgh, PA 15219, USA.ORCID 0000-0002-9226-4470

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
The Role of PIAS1 in EBV BiologyR01AI141410 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI LI, RENFENG · 2019 to 2023
$1.9M
ASB13 Control of EBV Life Cycle in B Cell and Epithelial Cell CancersR01AI187186 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Renfeng Li · 2025 to 2026
$1.4M
NCI NIH HHS P30 CA047904NIAID NIH HHS R01 AI141410NIAID NIH HHS R01 AI187186
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) establishes lifelong persistent infection in over 90% of the world's population. The virus persists as an episome in the host cells during latency and periodically reactivates through transcriptional activation of the immediate-early (IE) genes. While epigenetic regulation is central to maintaining viral latency, the host factors that enforce repression at these promoters remain incompletely defined. Here, we employed a novel Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/dCas9-based engineered DNA-binding molecule-mediated chromatin immunoprecipitation coupled with mass spectrometry (enChIP-MS) approach to identify proteins associated with the promoter of EBV IE gene

Identifiers

PMID42124621
PMCPMC13160016

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.